Skip to main content

Indaptus Therapeutics, Inc.

corporate_fare Company Profile

Indaptus Therapeutics, Inc.

INDP·NASDAQ·Life Sciences·CIK 0001857044

Indaptus Therapeutics, Inc. is a clinical biotechnology company focused on developing immunotherapy products to combat cancer and viral infections. Its primary product in development is Decoy20. This candidate is designed to be used either alone or in combination with other therapies to achieve lasting responses in various conditions. These include lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infections. Decoy20 is also being developed for the treatment of advanced solid tumors. The company, which was previously known as Intec Parent, Inc., adopted the name Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is based in New York, New York.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) is a publicly traded company in the Life Sciences sector. Wiseek monitors INDP SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Indaptus Therapeutics Reprices Over 1.6M Warrants to $1.75, Securing Votes for Critical Financing
  • Indaptus Therapeutics Reprices Warrants to $1.75 and Secures Votes for Dilutive Financing
  • Indaptus Seeks Shareholder Approval for Highly Dilutive $6M Financing, Ceding 96.4% Control to New Co-CEO David Lazar
  • Indaptus Therapeutics Co-CEO and CSO Salaries Cut to $60K Amidst Financial Restructuring
  • Indaptus Therapeutics Appoints Experienced Independent Director David Natan to Board and Audit Committee

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$20.85M
Diluted EPS
-$21.58
Op. Cash Flow
-$14.82M
Operating Income
-$19.83M
Cash & Equivalents
$8.51M
Debt / Equity
0.00×
Shares Outstanding
2.17M sh
Source: 10-K · filed 2026-03-17 · accession 0001493152-26-010585
$3.07 +0.04% today
52-week range · as of 2026-06-27 $0.92 – $13.44
Market cap
$343.12M
Volume
146.8K (0.1× avg)
3-mo avg 2M
Live data · 2026-07-06 04:55 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed INDP - Filings & News (Page 2)

INDP
Feb 12, 2026, 9:30 AM EST
Filing Type: 8-K
Importance Score:
9
Indaptus Therapeutics Reprices Over 1.6M Warrants to $1.75, Securing Votes for Critical Financing
Price at Filing: $1.78
Real-time Price: $3.07 info
Change: +$1.29 (+72%) info
Market Cap: $343.124M info
Sentiment: Negative
View Wiseek Article
INDP
Feb 12, 2026, 9:30 AM EST
Filing Type: DEFA14A
Importance Score:
9
Indaptus Therapeutics Reprices Warrants to $1.75 and Secures Votes for Dilutive Financing
Price at Filing: $1.78
Real-time Price: $3.07 info
Change: +$1.29 (+72%) info
Market Cap: $343.124M info
Sentiment: Negative
View Wiseek Article
INDP
Jan 21, 2026, 5:21 PM EST
Filing Type: DEF 14A
Importance Score:
10
Indaptus Seeks Shareholder Approval for Highly Dilutive $6M Financing, Ceding 96.4% Control to New Co-CEO David Lazar
Price at Filing: $2.65
Real-time Price: $3.07 info
Change: +$0.420 (+16%) info
Market Cap: $343.124M info
Sentiment: Negative
View Wiseek Article
INDP
Jan 20, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
Indaptus Therapeutics Co-CEO and CSO Salaries Cut to $60K Amidst Financial Restructuring
Price at Filing: $2.89
Real-time Price: $3.07 info
Change: +$0.180 (+6%) info
Market Cap: $343.124M info
Sentiment: Negative
View Wiseek Article
INDP
Jan 08, 2026, 5:26 PM EST
Filing Type: 8-K
Importance Score:
7
Indaptus Therapeutics Appoints Experienced Independent Director David Natan to Board and Audit Committee
Price at Filing: $3.05
Real-time Price: $3.07 info
Change: +$0.020 (+0.66%) info
Market Cap: $343.124M info
Sentiment: Positive
View Wiseek Article
INDP
Jan 08, 2026, 5:22 PM EST
Filing Type: PRE 14A
Importance Score:
10
Indaptus Therapeutics Seeks Shareholder Approval for $6M Financing, Leading to 95.6% Control by New Investor and Massive Dilution
Price at Filing: $3.03
Real-time Price: $3.07 info
Change: +$0.040 (+1%) info
Market Cap: $343.124M info
Sentiment: Negative
View Wiseek Article
INDP
Jan 02, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Indaptus Therapeutics Board Sees Three Directors Resign Ahead of Shareholder Meeting
Price at Filing: $2.74
Real-time Price: $3.07 info
Change: +$0.330 (+12%) info
Market Cap: $343.124M info
Sentiment: Neutral
View Wiseek Article